Biocon opens new research centre

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Biocon opens new research centre

Biosimilares/Novedades | Posted 23/04/2012 0 Post your comment

Indian biosimilars major Biocon, announced on 5 April 2012 the opening of a new state-of-the-art Integrated Research and Development Centre in Bangalore, India.

The centre is spread across 200,000 square feet and will include molecular biology, biologicals process science, formulations development, molecular characterisation and functional bioassay laboratories, as well as space for preclinical and clinical development groups.

Nobel Laureate Professor Kurt Wuthrich was present to inaugurate the centre, called the Biocon Research Centre (BRC), which aims to carry out ‘world class research on biologic[al]s that will address unmet medical needs.’

Biocon expects to recruit around 300 scientists to work at the BRC, who will be engaged in cutting edge biologicals research. According to Chairman and Managing Director of Biocon Group Ms Kiran Mazumdar-Shaw, Biocon aims ‘to galvanize the best talent available both in India and from across the globe, and offer them an intellectually stimulating environment combined with an enabling ecosystem to conduct path breaking research for biopharmaceuticals.’

BRC will also include an independent quality group, which will ensure compliance to Good Laboratory Practices and international regulatory guidelines for developing ‘best in class’ biologicals and biosimilars.

Biocon, which was established in 1978, is India’s largest biologicals company by revenue and one of the most advanced Indian players in the biosimilars field [1]. There are already more than 40 biologicals marketed in India, of which 25 are biosimilars. Acceptance of biosimilars in India is high and substitution is automatic, leading to speculation that India could be getting ready to dominate the global biosimilars market [2].

Related articles

Regulation of biosimilars in the US

Biocon announces Malaysia manufacturing plant

References

1. GaBI Online - Generics and Biosimilars Initiative. Hurdles to biosimilars in Asia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Apr 23]. Available from: www.gabionline.net/Biosimilars/General/Hurdles-to-biosimilars-in-Asia

2. GaBI Online - Generics and Biosimilars Initiative. Biotech growth and biosimilar opportunities in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Apr 23]. Available from: www.gabionline.net/Biosimilars/General/Biotech-growth-and-biosimilar-opportunities-in-India

Source: Biocon, The Hindi